<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824460</url>
  </required_header>
  <id_info>
    <org_study_id>PA-CL-03A</org_study_id>
    <secondary_id>75610</secondary_id>
    <nct_id>NCT00824460</nct_id>
  </id_info>
  <brief_title>Study of Phosphate Levels in Patients With Chronic Kidney Disease</brief_title>
  <acronym>PA21</acronym>
  <official_title>An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vifor Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the ability of different doses of PA21 to lower
      serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Serum-phosphate Levels at the End of Treatment.</measure>
    <time_frame>6 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum-phosphate Levels at Week 2</measure>
    <time_frame>2 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum-phosphate Levels at Week 4</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum-phosphate Levels at Week 5</measure>
    <time_frame>5 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1.25 g PA21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0 g PA21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5 g PA21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10.0 g PA21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>12.5 g PA21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer hydrochloride - active control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.25 g PA21 (250 mg iron)</intervention_name>
    <description>Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.</description>
    <arm_group_label>1.25 g PA21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5.0 g PA21 (1,000 mg iron)</intervention_name>
    <description>Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).</description>
    <arm_group_label>5.0 g PA21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7.5 g PA21 (1,500 mg iron)</intervention_name>
    <description>Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).</description>
    <arm_group_label>7.5 g PA21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10.0 g PA21 (2,000 mg iron)</intervention_name>
    <description>Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).</description>
    <arm_group_label>10.0 g PA21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 g PA21 (2,500 mg iron)</intervention_name>
    <description>Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).</description>
    <arm_group_label>12.5 g PA21</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer hydrochloride</intervention_name>
    <description>Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).</description>
    <arm_group_label>Sevelamer hydrochloride - active control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  â‰¥ 18 years of age,

          -  Receiving stable maintenance hemodialysis 3 times a week

          -  On restricted phosphate diet at screening and throughout study

          -  Receiving stable dose of phosphate binder for at least 1 month

          -  Serum phosphate levels &gt;1.78 mmol/L

        Main Exclusion Criteria:

          -  Uncontrolled hyperphosphatemia

          -  Hypercalcemia at screening or during washout

          -  Serum calcium &lt; 1.9 mmol/L (&lt;7.6 mg/dL)

          -  Severe hyperparathyroidism (iPTH levels &gt;600 ng/L)

          -  Pregnancy or lactation

          -  Iron deficiency anemia

          -  History of hemochromatosis or ferritin &gt;800 mg/L,

          -  Hepatitis B, hepatitis C or other significant concurrent liver disorders

          -  Known positivity to HIV

          -  Use of oral iron preparations 1 month before screening,

          -  Serious medical condition or uncontrolled systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Rudolf P Wutrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unafilliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Nephrology &amp; Metabolic Disease</name>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <zip>80002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complete Renal Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals / Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Houston Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haemodialysis at MHAT</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5th MHAT Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATCVD - National Cardiology Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1309</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Tokuda Hospital Sofia&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Alexandrovska&quot; Dialysis Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveta Anna&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MDHAT Department of Haemodialysis and Nephrology</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opca bonica Bjelovar</name>
      <address>
        <city>Bjelovar</city>
        <zip>43000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opca bolnica Karlovac</name>
      <address>
        <city>Karlovac</city>
        <zip>47000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opca bolnica</name>
      <address>
        <city>Koprivnica</city>
        <zip>48000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka bolnica Osijek</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Rijeka</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki bolnicki centar Split</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opca bolnica Zadar</name>
      <address>
        <city>Zadar</city>
        <zip>23000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka bolnica</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika Sveti Duh II</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicka bolnica Dubrava</name>
      <address>
        <city>Zagreb</city>
        <zip>10040</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innef a.s. Hemodialyzancni stredisko</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Nove Mesto na Morave</name>
      <address>
        <city>Nove MÄ›sto na Morave</city>
        <zip>59231</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice s poliklinikou v Novem Jicine</name>
      <address>
        <city>Novy Jicin</city>
        <zip>74101</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika nefrologie VFN</name>
      <address>
        <city>Prague</city>
        <zip>2</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologische Gemeinschaftspraxis und Dialysezentrum</name>
      <address>
        <city>Dortmund</city>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Golub-DobrzyÅ„</city>
        <zip>87-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Nefrologii</name>
      <address>
        <city>Katowice</city>
        <zip>40-027</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Dializa</name>
      <address>
        <city>Olkusz</city>
        <zip>32-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Nefrologii</name>
      <address>
        <city>PoznaÅ„</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Specjalistyczny</name>
      <address>
        <city>Siedlce</city>
        <zip>26</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Sieradz</city>
        <zip>98-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Dializy i Diagnostyki</name>
      <address>
        <city>Warszawa</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul Clinic Fundeni</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Universitar de Urgenta Bucuresti</name>
      <address>
        <city>Bucuresti</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic</name>
      <address>
        <city>Lasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Renamed Nefrodial SRL</name>
      <address>
        <city>Oradea</city>
        <zip>410562</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Avitum S.R.L</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GOU VPO Kazan</name>
      <address>
        <city>Kazan</city>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUZ City Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MLPU Clinical City Hospital</name>
      <address>
        <city>Smolensk</city>
        <zip>214001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg CUS City Mariinskaya Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg GUZ City Clinical Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GOU VPO</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195607</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg GUZ City Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GOU VPO</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUS City Hospital</name>
      <address>
        <city>St.Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuv Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>December 20, 2013</results_first_submitted>
  <results_first_submitted_qc>March 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2014</results_first_posted>
  <disposition_first_submitted>July 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 7, 2012</disposition_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1.25 g PA21 (250 mg Iron)</title>
          <description>Daily dose of 1.25 g PA21 (1 tablet)</description>
        </group>
        <group group_id="P2">
          <title>5.0 g PA21 (1,000 mg Iron)</title>
          <description>Daily dose of 5.0 g PA21 (4 tablets)</description>
        </group>
        <group group_id="P3">
          <title>7.5 g PA21 (1,500 mg Iron)</title>
          <description>Daily dose of 7.5 g PA21 (6 tablets)</description>
        </group>
        <group group_id="P4">
          <title>10.0 g PA21 (2,000 mg Iron)</title>
          <description>Daily dose of 10.0 g PA21 (8 tablets)</description>
        </group>
        <group group_id="P5">
          <title>12.5 g PA21 (2,500 mg Iron)</title>
          <description>Daily dose of 12.5 g PA21 (10 tablets)</description>
        </group>
        <group group_id="P6">
          <title>Sevelamer Hydrochloride - Active Control</title>
          <description>Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="24"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>For baseline characteristics data, from All Randomised patients was used.</population>
      <group_list>
        <group group_id="B1">
          <title>1.25 g PA21 (250 mg Iron)</title>
          <description>Daily dose of 1.25 g PA21 (1 tablet)</description>
        </group>
        <group group_id="B2">
          <title>5.0 g PA21 (1,000 mg Iron)</title>
          <description>Daily dose of 5.0 g PA21 (4 tablets)</description>
        </group>
        <group group_id="B3">
          <title>7.5 g PA21 (1,500 mg Iron)</title>
          <description>Daily dose of 7.5 g PA21 (6 tablets)</description>
        </group>
        <group group_id="B4">
          <title>10.0 g PA21 (2,000 mg Iron)</title>
          <description>Daily dose of 10.0g PA21 (8 tablets)</description>
        </group>
        <group group_id="B5">
          <title>12.5g PA21 (2,500 mg Iron)</title>
          <description>Daily dose of 12.5 g PA21 (10 tablets)</description>
        </group>
        <group group_id="B6">
          <title>Sevelamer Hydrochloride - Active Control</title>
          <description>Daily dose of 4.8 g sevelamer hydrochloride (6 tablets)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="24"/>
            <count group_id="B6" value="26"/>
            <count group_id="B7" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="12.29"/>
                    <measurement group_id="B2" value="59.7" spread="13.80"/>
                    <measurement group_id="B3" value="61.9" spread="13.71"/>
                    <measurement group_id="B4" value="60.6" spread="12.74"/>
                    <measurement group_id="B5" value="59.3" spread="12.32"/>
                    <measurement group_id="B6" value="61.1" spread="11.00"/>
                    <measurement group_id="B7" value="60.5" spread="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Serum-phosphate Levels at the End of Treatment.</title>
        <time_frame>6 weeks after baseline</time_frame>
        <population>For the Primary Outcome, data from the Full Analysis Set (FAS) was used. The FAS consists of all randomised subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>1.25 g PA21 (250 mg Iron)</title>
            <description>Daily dose of 1.25 g PA21 (1 tablet)</description>
          </group>
          <group group_id="O2">
            <title>5.0 g PA21 (1,000 mg Iron)</title>
            <description>Daily dose of 5.0 g PA21 (4 tablets)</description>
          </group>
          <group group_id="O3">
            <title>7.5 g PA21 (1,500 mg Iron)</title>
            <description>Daily dose of 7.5 g PA21 (6 tablets)</description>
          </group>
          <group group_id="O4">
            <title>10.0 g PA21 (2,000 mg Iron)</title>
            <description>Daily dose of 10.0 g PA21 (8 tablets)</description>
          </group>
          <group group_id="O5">
            <title>12.5g PA21 (2,500 mg Iron)</title>
            <description>Daily dose of 12.5 g PA21 (10 tablets)</description>
          </group>
          <group group_id="O6">
            <title>Sevelamer Hydrochloride - Active Control</title>
            <description>Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum-phosphate Levels at the End of Treatment.</title>
          <population>For the Primary Outcome, data from the Full Analysis Set (FAS) was used. The FAS consists of all randomised subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="0.650"/>
                    <measurement group_id="O2" value="-0.348" spread="0.684"/>
                    <measurement group_id="O3" value="-0.404" spread="0.391"/>
                    <measurement group_id="O4" value="-0.644" spread="0.551"/>
                    <measurement group_id="O5" value="-0.547" spread="0.584"/>
                    <measurement group_id="O6" value="-0.341" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum-phosphate Levels at Week 2</title>
        <time_frame>2 weeks after baseline</time_frame>
        <population>For this Secondary Outcome, FAS was used, which consists of all randomized subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).
Number of participants analyzed at this time point includes all subjects that had serum-phosphate measured at Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>1.25 g PA21 (250 mg Iron)</title>
            <description>Daily dose of 1.25 g PA21 (1 tablet)</description>
          </group>
          <group group_id="O2">
            <title>5.0 g PA21 (1,000 mg Iron)</title>
            <description>Daily dose of 5.0 g PA21 (4 tablets)</description>
          </group>
          <group group_id="O3">
            <title>7.5 g PA21 (1,500 mg Iron)</title>
            <description>Daily dose of 7.5 g PA21 (6 tablets)</description>
          </group>
          <group group_id="O4">
            <title>10.0 g PA21 (2,000 mg Iron)</title>
            <description>Daily dose of 10.0 g PA21 (8 tablets)</description>
          </group>
          <group group_id="O5">
            <title>12.5 g PA21 (2,500 mg Iron)</title>
            <description>Daily dose of 12.5 g PA21 (10 tablets)</description>
          </group>
          <group group_id="O6">
            <title>Sevelamer Hydrochloride - Active Control</title>
            <description>Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum-phosphate Levels at Week 2</title>
          <population>For this Secondary Outcome, FAS was used, which consists of all randomized subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).
Number of participants analyzed at this time point includes all subjects that had serum-phosphate measured at Week 2.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.55"/>
                    <measurement group_id="O2" value="-0.36" spread="0.35"/>
                    <measurement group_id="O3" value="-0.41" spread="0.40"/>
                    <measurement group_id="O4" value="-0.47" spread="0.62"/>
                    <measurement group_id="O5" value="-0.46" spread="0.45"/>
                    <measurement group_id="O6" value="-0.41" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum-phosphate Levels at Week 4</title>
        <time_frame>4 weeks after baseline</time_frame>
        <population>For this Secondary Outcome, FAS was used, which consists of all randomized subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).
Number of participants analyzed at this time point includes all subjects that had serum-phosphate measured at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>1.25 g PA21 (250 mg Iron)</title>
            <description>Daily dose of 1.25g PA21 (1 tablet)</description>
          </group>
          <group group_id="O2">
            <title>5.0g PA21 (1,000 mg Iron)</title>
            <description>Daily dose of 5.0g PA21 (4 tablets)</description>
          </group>
          <group group_id="O3">
            <title>7.5 g PA21 (1,500 mg Iron)</title>
            <description>Daily dose of 7.5g PA21 (6 tablets)</description>
          </group>
          <group group_id="O4">
            <title>10.0 g PA21 (2,000 mg Iron)</title>
            <description>Daily dose of 10.0g PA21 (8 tablets)</description>
          </group>
          <group group_id="O5">
            <title>12.5g PA21 (2,500 mg Iron)</title>
            <description>Daily dose of 12.5g PA21 (10 tablets)</description>
          </group>
          <group group_id="O6">
            <title>Sevelamer Hydrochloride - Active Control</title>
            <description>Daily dose of 4.8g sevelamer hydrochloride (6 tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum-phosphate Levels at Week 4</title>
          <population>For this Secondary Outcome, FAS was used, which consists of all randomized subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).
Number of participants analyzed at this time point includes all subjects that had serum-phosphate measured at Week 4.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.39"/>
                    <measurement group_id="O2" value="-0.39" spread="0.45"/>
                    <measurement group_id="O3" value="-0.32" spread="0.54"/>
                    <measurement group_id="O4" value="-0.58" spread="0.53"/>
                    <measurement group_id="O5" value="-0.53" spread="0.48"/>
                    <measurement group_id="O6" value="-0.53" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum-phosphate Levels at Week 5</title>
        <time_frame>5 weeks after baseline</time_frame>
        <population>For this Secondary Outcome, FAS population was used, which consists of all randomized subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).
Number of participants analyzed at this time point includes all subjects that had a serum-phosphate measurement at Week 5.</population>
        <group_list>
          <group group_id="O1">
            <title>1.25 g PA21 (250 mg Iron)</title>
            <description>Daily dose of 1.25 g PA21 (1 tablet)</description>
          </group>
          <group group_id="O2">
            <title>5.0 g PA21 (1,000 mg Iron)</title>
            <description>Daily dose of 5.0 g PA21 (4 tablets)</description>
          </group>
          <group group_id="O3">
            <title>7.5 g PA21 (1,500 mg Iron)</title>
            <description>Daily dose of 7.5 g PA21 (6 tablets)</description>
          </group>
          <group group_id="O4">
            <title>10.0 g PA21 (2,000 mg Iron)</title>
            <description>Daily dose of 10.0 g PA21 (8 tablets)</description>
          </group>
          <group group_id="O5">
            <title>12.5 g PA21 (2,500 mg Iron)</title>
            <description>Daily dose of 12.5 g PA21 (10 tablets)</description>
          </group>
          <group group_id="O6">
            <title>Sevelamer Hydrochloride - Active Control</title>
            <description>Daily dose of 4.8 g sevelamer hydrochloride (6 tablets)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum-phosphate Levels at Week 5</title>
          <population>For this Secondary Outcome, FAS population was used, which consists of all randomized subjects who received at least 1 dose of study treatment and had at least 1 post-baseline efficacy evaluation (while on treatment).
Number of participants analyzed at this time point includes all subjects that had a serum-phosphate measurement at Week 5.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.62"/>
                    <measurement group_id="O2" value="-0.51" spread="0.62"/>
                    <measurement group_id="O3" value="-0.40" spread="0.33"/>
                    <measurement group_id="O4" value="-0.57" spread="0.55"/>
                    <measurement group_id="O5" value="-0.58" spread="0.58"/>
                    <measurement group_id="O6" value="-0.52" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>For the serious adverse event (SAE) and adverse event (AE) listings, data from the Safety Set (SS) was used. The SS consists of all randomised subjects who received at least 1 dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>1.25 g PA21 (250 mg Iron)</title>
          <description>Daily dose of 1.25 g PA21 (1 tablet)</description>
        </group>
        <group group_id="E2">
          <title>5.0 g PA21 (1,000 mg Iron)</title>
          <description>Daily dose of 5.0 g PA21 (4 tablets)</description>
        </group>
        <group group_id="E3">
          <title>7.5 g PA21 (1,500 mg Iron)</title>
          <description>Daily dose of 7.5 g PA21 (6 tablets)</description>
        </group>
        <group group_id="E4">
          <title>10.0 g PA21 (2,000 mg Iron)</title>
          <description>Daily dose of 10.0 g PA21 (8 tablets)</description>
        </group>
        <group group_id="E5">
          <title>12.5 g PA21 (2,500 mg Iron)</title>
          <description>Daily dose of 12.5 g PA21 (10 tablets)</description>
        </group>
        <group group_id="E6">
          <title>Sevelamer Hydrochloride - Active Control</title>
          <description>Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faeces Discoloure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators may not present or publish partial or complete study results individually. Any manuscript or abstract proposed by the Investigators must be reviewed and approved in writing by Vifor Pharma before submission for publication. Names of all Investigators participating in the study will be included in the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Vifor Pharma</organization>
      <phone>41 58 851 8222</phone>
      <email>medinfo@viforpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

